Regulus Is On The Launch “Platform” With $20M Series A Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnylam, Isis keep ownership of joint venture for now, but status change could bring more investors aboard by 2011.
You may also be interested in...
AstraZeneca Taps Regulus For microRNA Drug Development
Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.
Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus
With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.
Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus
With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.